Triple agonist (GLP-1/GIP/glucagon)

About Novo Nordisk

Novo Nordisk has established itself as the dominant player in the diabetes and obesity treatment markets through its innovative GLP-1 receptor agonist portfolio. The company's purpose is to drive change to defeat diabetes and other serious chronic diseases, with a robust pipeline spanning multiple therapeutic areas including cardiovascular disease, rare blood disorders, and metabolic diseases. Recent regulatory approvals, including Wegovy HD (semaglutide 7.2 mg) providing 20.7% mean weight loss, demonstrate continued innovation and market expansion. The company maintains a strong financial position and is expanding global access to its treatments through strategic partnerships.

Therapeutic Areas